ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis
← catalyst calendarSponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
101actual
Sites
23
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-09-18 | actual | When the study began enrolling |
| Primary completion | 2020-10-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2018-05-07 | actual | When this record first appeared on the registry |
| Results posted | 2021-09-30 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-11-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Aortic Valve Stenosis
Intervention
- Device: TAVR with CENTERA THV
Primary outcome
what the primary-completion date above is the date OFAll-cause Death
measured 1 year
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2021-07-29 · 957 KB · Prot_SAP_000.pdf
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed